- CAS
- Purity
- 698387-09-6
- 99%
Location:Home > Pharmaceutical
Manufacturer supply good quality Neratinib 698387-09-6 with stock We provide high quality Neratinib (CAS 698387-09-6), at a very affordable prices to our customers.
The receptor tyrosine kinase HER2 (ErbB2) is a key component of epidermal growth factor receptor complexes that are known to have central roles in cell proliferation and cancer. Neratinib is an orally active, irreversible inhibitor of the HER2 kinase (IC50 = 59 nM). It also potently inhibits several mutants of HER2 and shows 10-fold or greater selectivity over a wide variety of other kinases. As an irreversible inhibitor, neratinib may circumvent acquired resistance developed against reversible inhibitors, including gefitinib . Neratinib has been evaluated in clinical trials against cancers characterized by HER2 overexpression or HER2 activating mutations.
An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Antitumor agent
The CAS number of Neratinib is 698387-09-6.
More information of Neratinib 698387-09-6 are:
|
CAS?Number |
698387-09-6 |
|
Density |
1.337 g/cm3 |
|
Boiling Point |
756.97 °C at 760 mmHg |
|
Flash Point |
411.601 °C |
|
Vapor Pressure |
0mmHg at 25°C |
|
Refractive Index |
1.667 |
|
HS CODE |
29334900 |
|
PSA |
112.40000 |
|
LogP |
6.07848 |
|
Pka |
12.37±0.43(Predicted) |
The chemical formula of?Neratinib is C30H29ClN6O3 which containing 30 Carbon atoms,29 Hydrogen atoms,1 Chlorine atoms,6 Nitrogen atoms and 3 Oxygen atoms,and the molecular weight, and the molecular weight of Neratinib is 557.052
The receptor tyrosine kinase HER2 (ErbB2) is a key component of epidermal growth factor receptor complexes that are known to have central roles in cell proliferation and cancer. Neratinib is an orally active, irreversible inhibitor of the HER2 kinase (IC50 = 59 nM). It also potently inhibits several mutants of HER2 and shows 10-fold or greater selectivity over a wide variety of other kinases. As an irreversible inhibitor, neratinib may circumvent acquired resistance developed against reversible inhibitors, including gefitinib . Neratinib has been evaluated in clinical trials against cancers characterized by HER2 overexpression or HER2 activating mutations.
InChI:InChI=1/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+
Relevant articles related to Neratinib:
|
Article |
Source |
|
Neratinib intermediate crystal as well as preparation method and application thereof |
- Paragraph 0088-0099, (2021/04/21) |
Hangzhou Share Chemical Co., Ltd is a quality supplier of Neratinib. Our main goal is customer satisfaction. Contact us to negotiate the best price for your business on Neratinib 698387-09-6.